• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection.严重失调的微生物生态系统的重置:粪便移植治疗复发性艰难梭菌感染
ISME J. 2014 Aug;8(8):1621-33. doi: 10.1038/ismej.2014.13. Epub 2014 Feb 27.
2
Faecal microbiota transplantation for infection: Four years' experience of the Netherlands Donor Feces Bank.粪便微生物群移植治疗 感染:荷兰供体粪便银行四年经验。
United European Gastroenterol J. 2020 Dec;8(10):1236-1247. doi: 10.1177/2050640620957765. Epub 2020 Sep 29.
3
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.
4
"Bacterial Consortium": A Potential Evolution of Fecal Microbiota Transplantation for the Treatment of Infection."细菌联合体": 用于治疗感染的粪便微生物群移植的一种潜在发展。
Biomed Res Int. 2022 Aug 8;2022:5787373. doi: 10.1155/2022/5787373. eCollection 2022.
5
Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.艰难梭菌感染粪便微生物群移植成功后微生物群组成、胆汁和脂肪酸代谢的变化
BMC Gastroenterol. 2018 Aug 28;18(1):131. doi: 10.1186/s12876-018-0860-5.
6
Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection.粪便微生物群移植治疗复发性艰难梭菌感染对管腔和黏膜微生物群以及常见获得性分类群的长期影响。
BMC Med. 2016 Oct 11;14(1):155. doi: 10.1186/s12916-016-0698-z.
7
Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study.复发性艰难梭菌感染患者单次粪便微生物群移植后失败的预测因素:一项为期 3 年的单中心队列研究结果。
Clin Microbiol Infect. 2017 May;23(5):337.e1-337.e3. doi: 10.1016/j.cmi.2016.12.025. Epub 2017 Jan 3.
8
Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy.随机临床试验:粪便微生物群移植治疗复发性艰难梭菌感染 - 来自一小批健康供体的新鲜、冷冻或冻干微生物群,通过结肠镜检查输送。
Aliment Pharmacol Ther. 2017 Apr;45(7):899-908. doi: 10.1111/apt.13969. Epub 2017 Feb 21.
9
Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.微生物群移植可恢复复发性艰难梭菌感染患者的正常粪便胆汁酸组成。
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9. doi: 10.1152/ajpgi.00282.2013. Epub 2013 Nov 27.
10
Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation.预测包裹粪菌移植后艰难梭菌感染的复发。
Microbiome. 2018 Sep 18;6(1):166. doi: 10.1186/s40168-018-0549-6.

引用本文的文献

1
Fecal microbiota transplantation as a therapeutic modality for recurrent infection: reviewing efficacy, safety, mechanisms of action, and outcomes.粪便微生物群移植作为复发性感染的一种治疗方式:疗效、安全性、作用机制及结果综述
Ann Med Surg (Lond). 2025 Jul 25;87(9):5829-5850. doi: 10.1097/MS9.0000000000003649. eCollection 2025 Sep.
2
Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions in infection (CDI), asymptomatic carriage and non-CDI diarrhea.宏基因组分析揭示了感染性(艰难梭菌感染)、无症状携带和非艰难梭菌感染性腹泻中具有多样化功能的肠道微生物群特征的不同模式。
Gut Microbes. 2025 Dec;17(1):2505269. doi: 10.1080/19490976.2025.2505269. Epub 2025 May 14.
3
Comparison of the gastrointestinal bacterial microbiota between dairy cows with and without mastitis.患乳腺炎和未患乳腺炎的奶牛胃肠道细菌微生物群的比较。
Front Microbiol. 2024 Mar 22;15:1332497. doi: 10.3389/fmicb.2024.1332497. eCollection 2024.
4
Vowst's FDA approval is a boon for the prevention of recurrent infection.Vowst获得美国食品药品监督管理局(FDA)的批准,这对预防复发性感染来说是一大福音。
Ann Med Surg (Lond). 2023 Oct 17;85(12):5852-5854. doi: 10.1097/MS9.0000000000001410. eCollection 2023 Dec.
5
Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.肠道微生物群及其代谢途径调节心血管疾病。
Front Microbiol. 2023 Sep 26;14:1272479. doi: 10.3389/fmicb.2023.1272479. eCollection 2023.
6
Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention of Infections.微生物群相关及感染控制方法在感染一级和二级预防中的应用
Microorganisms. 2023 Jun 9;11(6):1534. doi: 10.3390/microorganisms11061534.
7
Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial.粪便微生物群移植治疗溃疡性结肠炎维持缓解的随机对照试验。
World J Gastroenterol. 2023 May 7;29(17):2666-2678. doi: 10.3748/wjg.v29.i17.2666.
8
Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection.粪菌移植治疗复发性艰难梭菌感染的有益作用。
Cell Host Microbe. 2023 May 10;31(5):695-711. doi: 10.1016/j.chom.2023.03.019.
9
Is there a role for microbiome-based approach in common variable immunodeficiency?基于微生物组的方法在普通变异性免疫缺陷中是否有作用?
Clin Exp Med. 2023 Oct;23(6):1981-1998. doi: 10.1007/s10238-023-01006-3. Epub 2023 Feb 3.
10
Leveraging microbiome rediversification for the ecological rescue of soil function.利用微生物群落重新多样化实现土壤功能的生态修复。
Environ Microbiome. 2023 Jan 23;18(1):7. doi: 10.1186/s40793-023-00462-4.

本文引用的文献

1
Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.粪便替代物移植疗法根除艰难梭菌感染:“重新定植”肠道。
Microbiome. 2013 Jan 9;1(1):3. doi: 10.1186/2049-2618-1-3.
2
The long-term stability of the human gut microbiota.人类肠道微生物组的长期稳定性。
Science. 2013 Jul 5;341(6141):1237439. doi: 10.1126/science.1237439.
3
Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea.艰难梭菌感染和医院获得性腹泻中的肠道菌群失调和产丁酸菌减少。
J Clin Microbiol. 2013 Sep;51(9):2884-92. doi: 10.1128/JCM.00845-13. Epub 2013 Jun 26.
4
Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?粪便移植:一种安全可持续的临床治疗方法,可恢复人类疾病中的肠道微生物平衡?
Best Pract Res Clin Gastroenterol. 2013 Feb;27(1):127-37. doi: 10.1016/j.bpg.2013.03.003.
5
Fame and future of faecal transplantations--developing next-generation therapies with synthetic microbiomes.粪便移植的声誉和未来——用合成微生物组开发下一代疗法。
Microb Biotechnol. 2013 Jul;6(4):316-25. doi: 10.1111/1751-7915.12047. Epub 2013 Apr 10.
6
Human intestinal microbiota composition is associated with local and systemic inflammation in obesity.人体肠道微生物组成与肥胖相关的局部和全身炎症有关。
Obesity (Silver Spring). 2013 Dec;21(12):E607-15. doi: 10.1002/oby.20466. Epub 2013 Jun 22.
7
Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.粪菌移植治疗艰难梭菌感染:系统评价和荟萃分析。
Am J Gastroenterol. 2013 Apr;108(4):500-8. doi: 10.1038/ajg.2013.59. Epub 2013 Mar 19.
8
A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets.人体肠道类型指南:人类微生物组数据集微生物群落结构的荟萃分析。
PLoS Comput Biol. 2013;9(1):e1002863. doi: 10.1371/journal.pcbi.1002863. Epub 2013 Jan 10.
9
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
10
Long-term monitoring of the human intestinal microbiota composition.人类肠道微生物群组成的长期监测。
Environ Microbiol. 2012 Oct 15. doi: 10.1111/1462-2920.12023.

严重失调的微生物生态系统的重置:粪便移植治疗复发性艰难梭菌感染

Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection.

作者信息

Fuentes Susana, van Nood Els, Tims Sebastian, Heikamp-de Jong Ineke, ter Braak Cajo J F, Keller Josbert J, Zoetendal Erwin G, de Vos Willem M

机构信息

Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.

Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

ISME J. 2014 Aug;8(8):1621-33. doi: 10.1038/ismej.2014.13. Epub 2014 Feb 27.

DOI:10.1038/ismej.2014.13
PMID:24577353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4817604/
Abstract

Recurrent Clostridium difficile infection (CDI) can be effectively treated by infusion of a healthy donor faeces suspension. However, it is unclear what factors determine treatment efficacy. By using a phylogenetic microarray platform, we assessed composition, diversity and dynamics of faecal microbiota before, after and during follow-up of the transplantation from a healthy donor to different patients, to elucidate the mechanism of action of faecal infusion. Global composition and network analysis of the microbiota was performed in faecal samples from nine patients with recurrent CDI. Analyses were performed before and after duodenal donor faeces infusion, and during a follow-up of 10 weeks. The microbiota data were compared with that of the healthy donors. All patients successfully recovered. Their intestinal microbiota changed from a low-diversity diseased state, dominated by Proteobacteria and Bacilli, to a more diverse ecosystem resembling that of healthy donors, dominated by Bacteroidetes and Clostridium groups, including butyrate-producing bacteria. We identified specific multi-species networks and signature microbial groups that were either depleted or restored as a result of the treatment. The changes persisted over time. Comprehensive and deep analyses of the microbiota of patients before and after treatment exposed a therapeutic reset from a diseased state towards a healthy profile. The identification of microbial groups that constitute a niche for C. difficile overgrowth, as well as those driving the reinstallation of a healthy intestinal microbiota, could contribute to the development of biomarkers predicting recurrence and treatment outcome, identifying an optimal microbiota composition that could lead to targeted treatment strategies.

摘要

复发性艰难梭菌感染(CDI)可通过输注健康供体粪便悬液有效治疗。然而,尚不清楚哪些因素决定治疗效果。通过使用系统发育微阵列平台,我们评估了从健康供体移植到不同患者前后及随访期间粪便微生物群的组成、多样性和动态变化,以阐明粪便输注的作用机制。对9例复发性CDI患者的粪便样本进行了微生物群的整体组成和网络分析。在十二指肠输注供体粪便前后以及10周的随访期间进行了分析。将微生物群数据与健康供体的数据进行了比较。所有患者均成功康复。他们的肠道微生物群从以变形菌门和芽孢杆菌为主的低多样性疾病状态转变为更具多样性的生态系统,类似于健康供体的生态系统,以拟杆菌门和梭菌属为主,包括产丁酸细菌。我们确定了因治疗而减少或恢复的特定多物种网络和标志性微生物群。这些变化随时间持续存在。对患者治疗前后微生物群的全面深入分析揭示了从疾病状态到健康状态的治疗性重置。确定构成艰难梭菌过度生长生态位的微生物群以及那些推动健康肠道微生物群重新建立的微生物群,可能有助于开发预测复发和治疗结果的生物标志物,确定可导致靶向治疗策略的最佳微生物群组成。